SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a dengue vaccine be safe for autoimmune patients? new trial seeks answers
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing a live attenuated dengue vaccine (Butantan-DV) in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable and on low or no immune-suppressing drugs. Researchers want to see if the vaccine triggers a good immun…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated May 13, 2026 15:58 UTC
-
Steroid-Free hope: new lupus kidney treatment trial launches
Disease control Recruiting nowThis study tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus-related kidney disease as well as the standard treatment of oral steroids plus MMF, but without the side effects of long-term steroid use. About 196 people with activ…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 16, 2026 23:38 UTC
-
Experimental immune reset: could a single infusion tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting faulty B-cells. About 244 participan…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated May 16, 2026 23:35 UTC
-
Global study tracks lupus Drug's Real-World impact
Disease control Recruiting nowThis study follows 200 adults with systemic lupus erythematosus (SLE) who are starting anifrolumab as part of their normal treatment. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time to see how the drug performs outside of clinical …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: AstraZeneca • Aim: Disease control
Last updated May 16, 2026 23:35 UTC
-
Lupus patients get continued access to promising drug in new study
Disease control Recruiting nowThis study provides ongoing treatment with deucravacitinib for people with lupus (SLE or DLE/SCLE) who finished a previous study. It aims to keep managing the disease long-term. Only 35 participants who are likely to benefit and meet eligibility criteria will be enrolled.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 16, 2026 23:34 UTC
-
CAR-T therapy takes on autoimmune diseases: hope for lupus and sclerosis patients?
Disease control Recruiting nowThis early-stage study is testing a new treatment called CT1190B CAR-T cell therapy in 27 adults with severe lupus or sclerosis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune system. T…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 16, 2026 23:34 UTC
-
New 'Smart' drug aims to tame stubborn autoimmune diseases
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called CC312 in up to 18 adults with autoimmune diseases like lupus or rheumatoid arthritis that haven't improved with standard treatments. CC312 works like a bridge, guiding the body's immune cells to attack and destroy fault…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 16, 2026 23:33 UTC
-
New lupus drug PIT565 enters human safety trials
Disease control Recruiting nowThis early-stage study tests a new drug, PIT565, in 54 adults with active systemic lupus erythematosus (SLE) who haven't improved with standard treatments. The main goal is to check the drug's safety and how the body processes it. Participants will receive increasing doses of PIT…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 16, 2026 23:33 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CHT101, which uses specially engineered immune cells (CAR-T cells) to target and attack lupus-causing cells. It is for people with lupus that has not responded to standard treatments. The main goals are to see if it is safe and …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated May 16, 2026 23:32 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-phase study is testing a new treatment called universal CD19/20 CAR-T cells for people with moderate to severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and calm the overactive immune system. The …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 16, 2026 23:32 UTC
-
Cord blood stem cells could tame lupus – first human trial underway
Disease control Recruiting nowThis early-stage study tests a single injection of stem cells from donated umbilical cords in 10 adults with active lupus. The goal is to see if the treatment is safe and can reduce disease activity and improve kidney function. Participants continue their usual medications and ar…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: LiveKidney.Bio • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a cancer drug tame childhood lupus? small trial begins
Disease control Recruiting nowThis early-stage trial tests whether blinatumomab, a drug used for certain blood cancers, can safely control severe lupus in children. Six participants will receive two short courses of the drug and be monitored for a year. The goal is to see if it reduces disease activity and si…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Mao Jianhua • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could CAR-T cells tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-phase study tests a new treatment called BZE2204 for people with severe autoimmune diseases like lupus, myositis, and ITP that haven't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune s…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New pill could ease lupus skin flares in major trial
Disease control Recruiting nowThis study tests a new pill, enpatoran, for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can reduce skin disease severity and …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New cell therapy trial targets tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults aged 18-65 with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed cells. The main goal…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug VIS171 tested for lupus, hair loss, and kidney disease
Disease control Recruiting nowThis early-stage trial tests a new drug called VIS171 in 30 people with autoimmune diseases like lupus, alopecia areata, or a kidney condition. The main goal is to check if the drug is safe and tolerable when given as a shot under the skin. Participants will be followed for up to…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Engineered immune cells take on lupus in first human safety trial
Disease control Recruiting nowThis early-stage study tests a new treatment called universal CD19/20 CAR-T cells for people with moderate to severe lupus that hasn't responded to standard therapies. The therapy uses specially engineered immune cells to target and potentially calm the overactive immune system. …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New cell shot aims to tame Out-of-Control immune attacks
Disease control Recruiting nowThis early study tests a new cell treatment called YTS109 in 18 adults with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. Participants get a single infusion of these specially designed cells. The main goal is to see if the treatme…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New lupus drug candidate enters human trials
Disease control Recruiting nowThis study tests a new medicine called SSGJ-626 for people with systemic lupus erythematosus (SLE), an autoimmune disease. The drug targets a protein on certain immune cells to try to control the disease. About 198 adults aged 18-70 with SLE will receive either the drug or a plac…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New cell therapy takes on lupus and muscle disease in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called LUCAR-G79D for adults with lupus or inflammatory myopathies that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack disease-causing cells. The main goals are …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis early-phase study tests an experimental treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE) that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to target and p…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Qihan Biotech Co., Ltd. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Could a vitamin B3 pill tame lupus inflammation?
Disease control Recruiting nowThis study tests whether nicotinamide riboside (a form of vitamin B3) can reduce harmful inflammation in women with mild-to-moderate lupus. About 78 women will receive either the supplement or a placebo for 12 weeks. Researchers will measure changes in immune cell activity and bl…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Engineered immune cells aim to tame childhood autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK cells) in children aged 5 and older with severe rheumatic diseases like lupus that have not responded to standard therapies. The cells are designed to target and destroy faulty immune cells that caus…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Revolutionary In-Body CAR-T therapy targets autoimmune diseases
Disease control Recruiting nowThis early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and Sjögren's syndrome that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target a…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New injection shows promise for lupus patients in early trial
Disease control Recruiting nowThis study tests a new medicine, DB-2304, in healthy people and those with lupus (SLE or CLE). The goal is to check if it is safe and how the body processes it. About 148 adults will take part, and the study is currently recruiting.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
New lupus drug YK012 enters human trials – hope for patients with active disease
Disease control Recruiting nowThis study tests a new medicine, YK012, in 189 adults with moderate to severe lupus. The goal is to see if it is safe and can help control the disease. Participants will receive the drug and be monitored for side effects and how well their lupus responds. The trial is currently r…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New cell therapy aims to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in about 18 adults with autoimmune diseases like lupus that have not responded to standard therapies. Participants receive a single infusion of these specially designed cells. The main goal is to check safety and see…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New biologic combo shows promise for lupus kidney patients
Disease control Recruiting nowThis study tests whether newer biologic drugs (belimumab or telitacicept) can control active lupus kidney disease better than the standard medication mycophenolate mofetil. About 50 adults with biopsy-confirmed lupus nephritis will receive one of three treatments for 6 months. Th…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
Engineered immune cells take on lupus in first human trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goal is to check s…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to target and attack lupus-causing cells. It is for people with severe lupus that hasn't responded to standard therapies. The goal is to see if this approach can safely control the disease and reduce sy…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New lupus drug candidate enters human safety testing
Disease control Recruiting nowThis study is testing a new medicine, cizutamig, in people with systemic lupus erythematosus (SLE). The main goal is to check if it is safe and how the body handles it. About 47 adults with active lupus who have not responded well enough to other treatments will take part. This i…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New shot could tame lupus flares
Disease control Recruiting nowThis study tests an experimental drug called SG301, given as an injection under the skin, for people with systemic lupus erythematosus (SLE). About 120 adults whose lupus is not well controlled by standard treatments will receive either SG301 or a placebo. The main goal is to see…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New drug trial aims to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new drug, SAR448501/DR-0201, in 62 adults with lupus or rheumatoid arthritis. The goal is to find the safest and most effective dose by checking side effects and how the drug works in the body. Participants will be followed for about 13 months, and …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
Lupus breakthrough? CAR T-Cell trial targets young patients
Disease control Recruiting nowThis study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The goal …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated May 01, 2026 15:58 UTC
-
New study uses heart scans to spot early trouble in kids with lupus
Knowledge-focused Recruiting nowThis study looks at 60 children with lupus to find early signs of heart problems using non-invasive ultrasound techniques. The goal is to identify those at higher risk for heart issues. Participants must be under 18 and meet lupus criteria. The study does not offer treatment but …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated May 16, 2026 23:31 UTC
-
10,000 lupus patients needed for landmark online study
Knowledge-focused Recruiting nowThis study is a fully online registry for adults and children with lupus. It aims to collect information about diagnosis, treatment, and quality of life through surveys every six months. No travel is required—everything is done from home. The goal is to better understand lupus an…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Foundation of America • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC
-
Lupus drug may save fertility: survey launched
Knowledge-focused Recruiting nowThis study surveys 100 women under 40 with lupus who received a chemotherapy-like drug called cyclophosphamide. Some also got a hormone drug (GnRHa) to protect their ovaries. Researchers want to see if GnRHa helps prevent early menopause and infertility. No new treatments are giv…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated May 13, 2026 15:58 UTC
-
Massive lupus study launches to unlock disease secrets
Knowledge-focused Recruiting nowThis study is building a large database and sample bank from 3500 people with lupus. Researchers will use this information to better understand the disease and find new ways to treat it. Participants provide medical data and biospecimens over time.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Research Alliance • Aim: Knowledge-focused
Last updated May 05, 2026 11:55 UTC
-
Lupus patients who failed multiple drugs: are current treatments enough?
Knowledge-focused Recruiting nowThis study is observing 223 people with active lupus (including kidney inflammation) who have not improved with steroids and at least two immunosuppressants. Researchers will track how many achieve remission or low disease activity after 6 months of standard care. The goal is to …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Apr 26, 2026 19:36 UTC